HomeQuestion

Does the results of a PSMA scan affect the decision to start docetaxel chemotherapy in castrate sensitive metastatic prostate cancer?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?

How can you manage a patient with bilateral PCNs who requires Pluvicto administration?

In patients with NCCN-defined very high risk localized prostate adenocarcinoma who have a contraindication to abiraterone plus prednisone, do you consider starting ARPI (such as enzalutamide) instead, in addition to ADT?

How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?

How do you sequence Pluvicto vs docetaxel in a fit, chemotherapy-naïve patient with high-volume PSMA-avid mCRPC progressing on an ARPI?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.